TESTINCan: testicular cancer in Mexico
TESTINCan is the testicular cancer research platform at Mexico’s Instituto Nacional de Cancerología (INCan). It is CromGenLab’s clinical, molecular and imaging platform to study risk, prognosis and response to cisplatin chemotherapy in testicular germ cell tumors (TGCT), the most common solid cancer in young men.
Questions about TESTINCan
What is TESTINCan?
TESTINCan is CromGenLab’s testicular cancer research platform at the Instituto Nacional de Cancerología (INCan) in Mexico City. It brings together clinical, biological, molecular, environmental and imaging data from more than 4,000 patients with testicular germ cell tumors treated between 2007 and 2025.
What are testicular germ cell tumors?
They are the most common form of testicular cancer and the most frequent solid cancer in young men. They are classified as seminomas and non-seminomas; cisplatin-based chemotherapy is the standard treatment for advanced disease.
Why study cisplatin resistance?
Although most patients respond to cisplatin, some develop platinum resistance. TESTINCan searches for genetic, epigenetic and imaging biomarkers to anticipate who will respond and who needs other strategies.
Who leads TESTINCan?
TESTINCan is part of the Chromatin Regulation and Genomics Laboratory (CromGenLab), led by Dr. Rodrigo González Barrios de la Parra at INCan.
Registered protocols
TESTINCan publications
- 2026
Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing
Cuevas-Estrada B, Ríos-Rodríguez JA, García-Pacheco JA, Wegman-Ostrosky T, Cervera A, Alcaraz N, Montalvo-Casimiro M, Barrón-Hernández A, Castro-Hernández C, Jiménez-Ríos MA, Sobrevilla-Moreno N, Arriaga-Canon C, Herrera LA, González-Barrios R*.
NAR Cancer · 8(2):zcag007 · 2026
- 2026
Metabolic profile and skeletal muscle as predictors of survival in testicular germ cell tumors
Barrón-Hernández A, Ríos-Rodríguez JA, García-Pacheco JA, Cuevas-Estrada B, De-la-Rosa S, Castro-Hernández C, Jiménez-Ríos MA, Sobrevilla-Moreno N, Santibáñez-Andrade M, González-Barrios R*.
The Oncologist · 31(5):oyag072 · 2026
Manuscripts under review
- 2026
Hepatic radiomic-metabolic signature for platinum resistance in non-seminomatous testicular germ cell tumors
JNCI Cancer Spectrum · Under peer review
- 2026
Machine learning-assisted synthetic augmentation for rare-variant survival analysis: evidence from testicular cancer
American Journal of Epidemiology · Under review, revised version
- 2026
Industrial emissions and socioeconomic inequality in testicular cancer: associations with case rates, stage, and mortality in Mexico City
Journal of Hazardous Materials · With the editor
Earlier testicular cancer research
The lab’s earlier work on testicular germ cell tumors, since 2013.
Original articles 4
- 2023
Understanding sociodemographic factors among Hispanics through a population-based study on testicular cancer in Mexico
Ríos-Rodríguez JA, Montalvo-Casimiro M, Álvarez-López DI, Reynoso-Noverón N, Cuevas-Estrada B, Mendoza-Pérez J, Jiménez-Ríos MA, Wegman-Ostrosky T, Salcedo-Tello P, Scavuzzo A, Castro-Hernández C, Herrera LA, González-Barrios R*.
Journal of Racial and Ethnic Health Disparities · 2023
- 2022
Genomic profile in a non-seminoma testicular germ-cell tumor cohort reveals a potential biomarker of sensitivity to platinum-based therapy
González-Barrios R, Alcaraz N, Montalvo-Casimiro M, Cervera A, Arriaga-Canon C, Munguía-Garza P, Hinojosa-Ugarte D, Sobrevilla-Moreno N, Torres-Arciga K, Mendoza-Pérez J, Díaz-Chávez J, Cortés-González CC, Castro-Hernández C, Martínez-Cedillo J, Scavuzzo A, Pérez-Montiel D, Jiménez-Ríos MA, Herrera LA.
Cancers (Basel) 14(9):2065 · 2022
- 2016
MAD2γ, a novel MAD2 isoform, reduces mitotic arrest and is associated with resistance in testicular germ cell tumors
López-Saavedra A, Ramírez-Otero M, Díaz-Chávez J, Cáceres-Gutiérrez R, Justo-Garrido M, Andonegui MA, Mendoza J, Downie-Ruíz Á, Cortés-González C, Reynoso N, Castro C, Domínguez-Gómez G, Santibáñez-Andrade M, Fabián-Morales E, Pruefer F, Luna-Maldonado F, González-Barrios R, Herrera LA.
Cell Cycle · 2016
- 2013
Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
Mendoza J, Martínez J, Hernández C, Pérez-Montiel D, Castro C, Fabián-Morales E, Santibañez M, González-Barrios R, Díaz-Chávez J, Andonegui MA, Reynoso N, Oñate LF, Jiménez MA, Núñez M, Dyer R, Herrera LA.
British Journal of Cancer 109(1):68–75 · 2013
Review articles 1
- 2023
Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in TGCT patients
Cuevas-Estrada B, Montalvo-Casimiro M, Munguía-Garza P, Ríos-Rodríguez JA, González-Barrios R*, Herrera LA.
International Journal of Molecular Sciences 24(9):7873 · 2023